Future studies should be conducted to investigate a possible implication of iNOS variants in the risk of suffering from pancreatic cancer and the use of both eNOS and iNOS as therapeutic targets in patients with high expressions of these components. Here, NOS3 is linked to familial pancreatic carcinoma.